Pipeline
We focus on developing targeted alpha radiotherapeutics for patients with high unmet needs.
Co-development*
MP0712 / 212Pb x DLL3 Radio-DARPin Therapy: SCLC and neuroendocrine tumors
MP0712 is a targeted alpha radiotherapy directed specifically against DLL3 (delta-like ligand 3), a validated target expressed in more than 85% of patients with small cell lung cancer (SCLC).
Despite recent advances in the treatment of SCLC, there is still a high unmet need for patients not responding or relapsing from bispecific T-cell engagers or antibody-drug conjugates (ADC).
MP0712 delivers the potent alpha-emitting therapeutic isotope 212Pb in a targeted manner to DLL3-expressing tumor cells, thereby killing tumor lesions and minimizing impact on healthy tissues. MP 0712 is half-life optimized to leverage DLL3 internationalization and replenishment for optimal tumor uptake and accumulation. This powerful mode of action offers the potential to significantly improve treatment options for these patients.
MP0712 is currently being evaluated in a US multi-site Phase 1/2a study in patients with SCLC and other DLL3-expressing neuroendocrine cancers (https://clinicaltrials.gov/study/NCT07278479).
MP0712 is being co-developed by Molecular Partners and our strategic partner Orano Med, a pioneer in targeted alpha therapy.
MP0726 / MSLN Radio-DARPin Therapy: Ovarian cancer
MP0726 is a radiopharmaceutical delivering a potent alpha-emitting therapeutic isotope to mesothelin (MSLN) expressing tumors. MSLN is a tumor target highly expressed in patients with ovarian cancer (>80% prevalence), and its expression is maintained in metastases.
Molecular Partners has designed MP0726 to selectively target and bind to the membrane proximal epitope of MSLN to avoid impact from high shedding, a potential challenge for the development of therapeutics against MSLN.
MP0726 is advancing to first-in-human imaging in H2 2026.
MP0730 / CD70 Radio-DARPin Therapy: Kidney cancer and other CD70-expressing indications
MP0730 is a radiopharmaceutical designed to deliver a potent alpha-emitting therapeutic isotope to CD70-expressing tumors. CD70 is a clinically validated target, demonstrated through CAR-T cell therapies, and is overexpressed in clear cell renal cell carcinoma (ccRCC), a type of kidney cancer, and other solid tumors.
CD70 expression is maintained in metastases and limited in healthy tissues. This makes it an ideal target for targeted alpha therapy, which has the potential to overcome resistance mechanisms reported for chemotherapy and other therapeutic modalities in ccRCC.
MP0730 is being developed with an isotope-agnostic approach and a first-in-human program is expected to start mid 2027.
*The strategic collaboration with Orano Med includes DLL3, with the option to extend it to additional programs.
**Compassionate care at NuMeRI (South Africa)
Our next-generation immune cell engagers, including Switch-DARPins,provide upside potential and value creation opportunities.
MP0317 / FAP x CD40: Advanced Solid Tumors
MP0317 is a localized CD40 agonist designed to activate immune cells specifically within the tumor microenvironment by anchoring to fibroblast activation protein (FAP) which is found at high density in the tumor stroma. This tumor-localized mechanism of action aims to achieve greater activity with fewer side effects compared to systemic CD40-targeting therapies.
MP0317 is currently being evaluated in an investigator-initiated, proof-of-concept Phase 2 study in combination with standard-of-care (SoC) for the treatment of patients with advanced cholangiocarcinoma (https://clinicaltrials.gov/study/NCT07036380). The study is a randomized, multicenter study in France with the objective to assess the clinical benefit of MP0317 combined with SoC, which comprises the immunotherapy durvalumab (an anti-PD-L1 checkpoint inhibitor) plus gemcitabine-cisplatin-based chemotherapy. The tumor microenvironment (TME) is known to play a crucial role in cholangiocarcinoma development and treatment resistance. MP0317 is hypothesized to lead to immune-mediated reshaping of the TME, thereby improving the 12-month progression-free survival rate of patients compared to those treated with SoC only.
Mechanism of Action
MP0533 / CD33 x CD123 x CD70 x CD3: r/r AML and AML/MDS
MP0533 is a novel tetra-specific T cell engager designed to kill all acute myeloid leukemia (AML) cells – blasts and also leukemic stem cells known to drive relapse – while minimizing damage to healthy cells. MP0533 targets three antigens preferentially co-expressed on AML cells. The strength of binding to cells increases with the number of targets engaged, thereby strongly favoring binding to AML cells over healthy cells.
MP0533 is currently being evaluated in a Phase 1/2a study in patients with relapsed/refractory AML or myelodysplastic syndrome (MDS) (https://clinicaltrials.gov/study/NCT05673057).
Mechanism of Action
MP0632 / CD3 x CD2 x MSLN X EpCAM Switch-DARPin
MP0632 is a logic-gated Switch-DARPin T-cell engager (TCE), designed to achieve conditional tumor-localized immune activation targeting MSLN and EpCAM, which are highly co-expressed in ovarian cancer and other solid tumors. The CD3-engaging DARPin is unmasked (“Switched” on) and activates T cells only upon binding to both MSLN and EpCAM. MP0632 is half-life extended through a Fc domain, which broadens the Company’s capabilities in half-life engineering modalities.
